Dr. Tagawa on pivotal trials supporting use of 177Lu-PSMA-617 in prostate cancer

Scott T. Tagawa, MD, MS, FACP, discusses the pivotal VISION and TheraP trials that supported the FDA approval of 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting. Tagawa is a professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.